Neuronetics, Inc. STIM
1.24 USD -0.01 (-0.80%)
Regular-session close
1.24 0.00 -0.02%
After hours · Nov 19, 7:40 PM ET
1.23 Day range 1.34
0.80 52-week range 3.44
- YTD
- -10.14%
- 1 year
- -16.78%
News
zacks.com Here's Why Neuronetics (STIM) is Poised for a Turnaround After Losing 37.8% in 4 Weeks Neuronetics (STIM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in…
globenewswire.com Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Bullfrog AI Hldgs (NASDAQ:BFRG) stock moved upwards by 21.2% to $0.5 during Wednesday's pre-market session. The company's market cap stands at $7.6 million. As per the press release, Q3…
zacks.com Neuronetics (STIM) Loses 34.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Neuronetics (STIM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) stock increased by 13.2% to $1.29 during Wednesday's pre-market session. The company's market cap stands at $5.4 million. The company's, Q2 earnings came…
globenewswire.com Neuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common Stock MALVERN, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the pricing of its previously announced underwritten public offering of its common…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 13.9% to $2.2 during Tuesday's after-market session. The company's market cap stands at $73.3 million. Longeveron (NASDAQ:LGVN) stock…benzinga.com Neuronetics Announces Credit Agreement Amendments And Public Offering Of Shares; Size Not Disclosed Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics"), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook…
globenewswire.com Neuronetics Announces Proposed Public Offering of Common Stock MALVERN, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology…benzinga.com B. Riley Securities Maintains Buy on Neuronetics, Raises Price Target to $6 B. Riley Securities analyst Madison El-Saadi maintains Neuronetics (NASDAQ:STIM) with a Buy and raises the price target from $5 to $6.
seekingalpha.com Neuronetics, Inc. (STIM) Q3 2026 Earnings Call Transcript Neuronetics, Inc. (STIM) Q3 2026 Earnings Call Transcript
globenewswire.com Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through…
marketbeat.com Neuronetics Q3 Earnings Call Highlights Neuronetics NASDAQ: STIM reported third-quarter 2026 revenue growth, wider gross margin and a return to positive adjusted EBITDA, citing record NeuroStar system sales and continued revenue-cycle…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma…
zacks.com Neuronetics (STIM) Reports Q3 Loss, Tops Revenue Estimates Neuronetics (STIM) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.13 per share a year ago.
benzinga.com Neuronetics Q3 2026 Earnings Call Transcript Neuronetics (NASDAQ:STIM) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…benzinga.com Neuronetics Q3 EPS $(0.02) Beats $(0.09) Estimate, Sales $41.962M Beat $40.425M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.09) by 77.78 percent. This is a 84.62 percent increase over losses of $(0.13)…
benzinga.com Neuronetics Affirms FY2026 Sales Guidance of $160.000M-$164.000M vs $162.025M Est Neuronetics (NASDAQ:STIM) affirms FY2026 sales outlook from $160.000 million-$164.000 million to $160.000 million-$164.000 million vs $162.025 million estimate.
globenewswire.com Neuronetics Reports Third Quarter 2026 Financial and Operating Results MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology…
globenewswire.com Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call MALVERN, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through…
defenseworld.net Neuronetics, Inc. (NASDAQ:STIM) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages Shares of Neuronetics, Inc. (NASDAQ: STIM - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the stock, Marketbeat reports. One…
globenewswire.com NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System MALVERN, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through…
seekingalpha.com Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript
marketbeat.com Neuronetics Q2 Earnings Call Highlights Neuronetics NASDAQ: STIM reported second-quarter 2026 revenue growth, a sharply narrower net loss and positive adjusted EBITDA as its Greenbrook clinic business expanded and the company introduced…
zacks.com Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates Neuronetics (STIM) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.15 per share a year ago.
globenewswire.com Neuronetics and Jorey Chernett Announce Shared Vision MALVERN, Pa., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics” or the “Company”) and Jorey Chernett, the Company's second largest shareholder and Managing Member of…
globenewswire.com Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through…
globenewswire.com Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland New location expands access to advanced mental health treatments while serving as Greenbrook's flagship innovation center and blueprint for future care delivery New location expands access to…
globenewswire.com Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through…
